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Abstract
Background: Phase III trials evaluating the efficacy of gefitinib (IRESSA) in non-small cell lung
cancer (NSCLC) lend support to the need for improved patient selection in terms of gefitinib use.
Mutation of the epidermal growth factor receptor (EGFR) gene is reported to be associated with
clinical responsiveness to gefitinib. However, gefitinib-sensitive and prolonged stable-disease-
defined tumors without EGFR gene mutation have also been reported.
Methods: To identify other key factors involved in gefitinib sensitivity, we analyzed the protein
expression of molecules within the EGFR family, PI3K-Akt and Ras/MEK/Erk pathways and
examined the sensitivity to gefitinib using the MTT cell proliferation assay in 23 lung cancer cell
lines.
Results: We identified one highly sensitive cell line (PC9), eight cell lines displaying intermediate-
sensitivity, and 14 resistant cell lines. Only PC9 and PC14 (intermediate-sensitivity) displayed an
EGFR gene mutation including amplification. Eight out of the nine cell lines showing sensitivity had
Akt phosphorylation without ligand stimulation, while only three out of the 14 resistant lines
displayed this characteristic (P = 0.0059). Furthermore, the ratio of phosphor-Akt/total Akt in
sensitive cells was higher than that observed in resistant cells (P = 0.0016). Akt phosphorylation
was partially inhibited by gefitinib in all sensitive cell lines.
Conclusion: These results suggest that Akt phosphorylation without ligand stimulation may play
a key signaling role in gefitinib sensitivity, especially intermediate-sensitivity. In addition, expression
analyses of the EGFR family, EGFR gene mutation, and FISH (fluorescence in situ hybridization)
analyses showed that the phosphorylated state of EGFR and Akt might be a useful clinical marker
of Akt activation without ligand stimulation, in addition to EGFR gene mutation and amplification,
particularly in adenocarcinomas.
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Background
Gefitinib(IRESSA) [4-(3-chloro-4-fluoroanilino)-7-meth-
oxy-6-(3-morpholinopropoxy)-quinazoline] is an orally
active, epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor that inhibits EGFR signaling [1,2]. IDEAL
(IRESSA Dose Evaluation in Advanced Lung cancer) 1 and
2 were randomized Phase II trials in patients with non-
small cell lung cancer (NSCLC) refractory to platinum-
based chemotherapy. These trials demonstrated that gefit-
inib was active and generally well tolerated [3,4]. How-
ever, ISEL (IRESSA Survival Evaluation in Lung cancer), a
Phase III trial evaluating the efficacy of gefitinib compared
to best supportive care for refractory or recurrent NSCLC,
failed to demonstrate a significant survival benefit, except
in an Eastern subpopulation and in those who had never
smoked [5]. These data indicate that improved patient
selection and combination strategies are probably
required to maximize the benefits of using this targeted
therapy.
Gefitinib exerts its antitumor activity through the inhibi-
tion of EGFR tyrosine kinase; however, this activity does
not significantly correlate with the level of EGFR expres-
sion by the tumor cell [6]. Recent reports have shown that
there are differences between gefitinib responders and
non-responders in the frequency of activating mutations
in the EGFR  gene, which suggests that such mutations
might be predictive markers for sensitivity to gefitinib
[7,8]. EGFR  gene amplification, as detected by fluores-
cence in situ hybridization (FISH), was also reported to be
a predictive marker [9]. However, there are known to be
gefitinib-sensitive and intermediate-sensitive tumors that
have no activating mutations in the EGFR gene, including
gene amplification. Thus, it is likely that other factors in
lung cancer cells may sensitize cells to gefitinib in addi-
tion to EGFR  gene mutation and the amplification
detected by FISH. In order to identify additional key mol-
ecules involved in gefitinib resistance, we examined the
sensitivity to gefitinib of 23 lung cancer cell lines using the
3- [4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) cell proliferation assay and identified sen-
sitive, intermediate-sensitive, and resistant lung cancer
cell lines. A few reports have suggested that small cell lung
cancer(SCLC) is responsive to gefitinib [10,11]. Tanno et
al reported that MAPK, a downstream effector of the EGFR
was inhibited by gefitinib in SCLC cell lines that expressed
the EGFR even at a very low level[11]. SCLC cell lines were
included in our series. We also analyzed the genomic sta-
tus of the EGFR gene mutation and EGFR gene amplifica-
tion, as well as the protein expression level of key
molecules in the EGFR family (EGFR, Her2, Her3), PI3K-
Akt (Akt and phosphatase and tensin homolog [PTEN])
and Ras/MEK/Erk pathways (p44/42 mitogen-activated
protein [MAP] kinase, p38 MAP kinase) which act down-
stream of EGFR. We correlated the cytotoxic activity of
gefitinib in our 23 lung tumor cell lines to the correspond-
ing expression patterns of these proteins.
Methods
Cell Lines
Twenty-three lung cancer cell lines were used in this study.
They comprised: 10 adenocarcinoma cell lines (ABC-1,
A549, PC3, PC7, RERF-LCMS, RERF-LCKJ, LCD, LCOK,
PC9, and PC14), eight squamous-cell carcinoma cell lines
(QG56, EBC-1, LK-2, LC-1/sq, PC1, RERF-LCAI, PC10,
and SQ5), and five small-cell carcinoma cell lines (NCI-
H69, SBC3, NCI-N231, Lu135, and MS-1). The Lu135 cell
line was provided by Y. Shimosato and T. Terasaki, and
the LCD and LCOK cell lines by S. Hirohashi (National
Cancer Center Research Institute, Tokyo, Japan). The NCI-
N231, A549, and NCI-H69 cell lines were obtained from
the American Type Culture Collection (Rockville, MD)
[12,13]. The PC1, PC3, PC7, PC9, PC10, PC14, and QG56
cell lines were obtained from IBL (Gunma, Japan). The
RERF-LCKJ, SQ5, LC-1/sq, RERF-LCAI, and MS-1 cell lines
were obtained from RIKEN Cell Bank (Ibaragi, Japan).
The ABC-1, RERF-LCMS, LK-2, EBC-1, and SBC3 cell lines
were obtained from the Health Science Research
Resources Bank (Osaka, Japan).
In order to determine the activation of the members
downstream of EGFR without ligand stimulation, all cell
lines were separately cultured in serum-containing (+)
and serum-free (-) conditions for 24 h.
Drugs and Growth-Inhibition Assay
Gefitinib was provided by AstraZeneca and dissolved in
dimethyl sulfoxide (DMSO) for in vitro studies. We used
the colorimetric MTT assay to examine the activity of gefit-
inib against all 23 lung cancer cell lines as previously
reported [14]. Cell suspensions (200 µl, 105 cells/ml)
were seeded into 96-well microtiter plates and 10 µl of
drug solution added, at various concentrations. After incu-
bation for 72 h at 37°C, 20 µl of MTT solution (5 mg/ml
in phosphate buffered saline [PBS]) was added to each
well and incubation then continued for a further 4 h at
37°C. The IC50 value was defined as the concentration of
gefitinib needed for a 50% reduction in absorbance (560
nm) based on cell growth curves.
Western Blot Analysis
Western blot analysis was performed as previously
described [15]. The membranes were first incubated over-
night at 4°C with antibody specific for the following pri-
mary antibodies: PTEN (Santa Cruz Biotechnology, Santa
Cruz, CA) and Akt, phospho-Akt (Ser473), p42/44 MAP
kinase and phospho-p44/42 MAP kinase (Thr202/
Tyr204), p38 MAP kinase and phospho-p38 MAP kinase
(Thr180/Tyr182),  β-actin, EGFR, and phospho-EGFR
(Y1068), Her2 and Her3 [all from Cell Signaling Technol-BMC Cancer 2006, 6:277 http://www.biomedcentral.com/1471-2407/6/277
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ogy, Beverly, MA]. The membranes were then incubated
with peroxidase-conjugated secondary antibodies and
protein was detected with enhanced chemiluminescence
(ECL) Western blotting detection reagents (Amersham,
Buckinghamshire, UK) [16,17]. These images were quan-
tified by measuring signal intensity using National Insti-
tute of Health (NIH) Image (ImageJ1.32j). The ratios of
phospho-EGFR/EGFR, Her2/β-actin, Her3/β-actin, phos-
pho-Akt/Akt, PTEN/β-actin, phospho-p44/42 MAP
kinase/p44/42 MAP kinase, and phospho-p38 MAP
kinase/p38 MAP kinase were calculated from cells grown
in both serum-containing (+) and serum-free (-) condi-
tions.
Polymerase Chain Reaction Single Strand Conformation 
Polymorphism Analyses and Sequencing of Genomic DNA
Genomic DNA samples were obtained from each cell line
by proteinase K treatment and phenol chloroform extrac-
tion using standard protocols [17]. From each genomic
DNA sample, exons 18, 19 and 21 of the EGFR gene and
exon 1 and 2 of the K-Ras gene were amplified separately
with the relevant polymerase chain reaction (PCR) prim-
ers [7,18] using the Gene Amp XL PCR kit (Perkin Elmer/
Roche, Branchburg, NJ). PCR conditions for genomic
DNA analysis were as follows: 40 cycles at 94°C for 40 sec-
onds, 60°C for 30 seconds, and 68°C for 90 seconds, fol-
lowed by 68°C for 8 minutes. Fluorescein-isothiocyanate
(FITC)-labeled PCR products were denatured, cooled on
ice, and loaded on neutral 6% polyacrylamide gels with or
without 5% (vol/vol) glycerol, as described previously
[13]. After electrophoresis, the gels were analyzed with the
FluorImager 595 (Molecular Dynamics Inc., Sunnyvale,
CA). Each DNA sample was examined with three primer
pair combinations, with the M13 sequence (TGTAAAAC-
GACGACGGCCAGT) added in each case to the appropri-
ate primer. PCR analysis was performed as described
above, with the resulting products being purified and
sequenced by fluorescence-based automated sequencing
(Perkin Elmer/Applied Biosystems, Foster City, CA).
FISH Analysis
Cells were fixed on slides in Carnoy's fluid (60% ethanol;
30% chloroform; 10% acetic acid) and incubated for 30
min at 60°C and 30 min at 37°C in 2 × sodium chloride
sodium citrate solution (SSC)/0.1%Tween20 followed by
ethanol dehydration. The LSI EGFR/CEP7 SpectrumGreen
Probe (Vysis Downers Grove, IL) was applied to the slides
[9] which were then incubated for 5 min at 75°C for the
codenaturation of probe and chromosomal DNA. Hybrid-
ization proceeded overnight at 37°C, after which the
slides were washed in 50% formamide/2 × SSC for 15
min, 2 × SSC for 10 min and 2 × SSC/0.1%Tween29 for 5
min at 47°C. The chromatin was counterstained with 4'6'-
diamidino-2-phenylindole (DAPI) (Roche). The fre-
quency of tumor cells with specific copy numbers of the
EGFR gene (red signal) and chromosome 7 (green signal)
were estimated under a BX61 Olympus fluorescence
microscope in a minimum of 200 nuclei. A gene amplifi-
cation was defined as gene/chromosome per cell ratio >2
or >15 copies of EGFR per cell in >10% of analyzed cells.
EGFR gene copy numbers were counted and were classi-
fied into six FISH strata by Hirsh's criteria [9,19].
Exposure to Gefitinib
Lung cancer cell lines were serum-starved for 24 h and
treated with various concentrations of gefitinib (0, 0.1, 1
and 10 µM/ml) for 2 h before exposure to 10 ng/ml epi-
dermal growth factor (EGF; [BA-53, Santa Cruz Biotech-
nology]) for 5 min in order to evaluate the effect of
gefitinib on the PI3K-Akt and Ras/MEK/Erk pathways.
These images were quantified by measuring signal inten-
sity using NIH Image (ImageJ1.32j).
Statistical Analysis
The Chi-square test was used to evaluate the relationship
between gefitinib sensitivity and activation of the mole-
cules in the EGFR family, PI3K-Akt and Ras/MEK/Erk
pathways. The cut-off value of signal intensity measured
by NIH Image was defined by Receiever Operating Char-
acteristics (ROC)curve. The expression ratio of phospho-
EGFR/EGFR, Her2/β-actin, Her3/β-actin, phospho-Akt/
Akt, phospho-p44/42 MAP kinase/p44/42 MAP kinase,
phospho-p38 MAP kinase/p38 MAP kinase and PTEN/β-
actin was compared between gefitinib-resistant and gefit-
inib-sensitive cell lines using the Mann-Whitney test. In
addition, the correlations between PTEN expression and
phosphorylation of Akt were examined by Spearman's
rank order coefficient across all 23 cell lines. P < 0.05 was
considered to be statistically significant.
Results
Effect of Gefitinib on Cell Growth In Vitro
The IC50 values of gefitinib for the 23 lung cancer cell
lines, as determined by MTT assay, are summarized in Fig.
1. Only the PC9 cell line had an IC50 of <1 µmol/L
(highly-sensitive), 14 cell lineshad an IC50 of >10 µmol/L
(resistant), and the remaining eight had an IC50 of 1 to 10
µmol/L (intermediate-sensitive).
Expression and Phosphorylation Status of EGFR, Her2, 
Her3, Akt, p44/42, p38 MAP kinase, and PTEN in Gefitinib-
sensitive Versus Gefitinib-resistant Cell Lines
The protein expression levels and phosphorylation status
of EGFR, Her2, Her3, Akt, p44/42, p38 MAP kinase, and
PTEN were analyzed in all 23 lung cancer cell lines by
measuring the signal intensity using NIH Image
(ImageJ1.32j) (Figs. 2, 3, 4 and 5). To evaluate activation
without ligand stimulation, the cell lines were cultured in
serum-containing (+) and serum-free (-) conditions. The
ratios of phospho-EGFR/EGFR, Her2/β-actin, Her3/β-BMC Cancer 2006, 6:277 http://www.biomedcentral.com/1471-2407/6/277
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actin, phospho-Akt/Akt, PTEN/β-actin, phospho-p44/42
MAP kinase/p44/42 MAP kinase, and phospho-p38 MAP
kinase/p38 MAP kinase were calculated in cells grown
under both conditions. Across the entire cohort of 23 lung
cancer cell lines, those showing sensitivity to gefitinib
exhibited greater phosphorylation of Akt and EGFR with-
out ligand stimulation than gefitinib-resistant cell lines,
according to the Mann-Whitney test (P  = 0.0016, P  =
0.0274, respectively) (Figs. 3 and 5). Furthermore, the
ratio of phospho-Akt/total Akt in intermediate-sensitive
cells was higher than that observed in resistant cells (P =
0.003). There was no statistical difference in the phospho-
rylation of p44/42 MAP kinase, p38 MAP kinase without
ligand stimulation, and expression of PTEN, Her2 and
Her3 (Mann-Whitney test: PTEN: P = 0.8; p-p44/42: P =
0.8; p-p38: P  = 0.45; Her2:P  = 0.052; Her3:P  = 0.08,
respectively) (Fig. 3, 4 and 5). As shown in Table 1, gefit-
inib-sensitive cells frequently expressed phospho-Akt,
phospho-EGFR and Her2 with ligand stimulation (P =
0.0059, P = 0.0319; P = 0.0344, Chi-square test). In par-
ticular, cell lines characterized by phosphorylation of Akt
without ligand stimulation had a greater than 29 times
probability of being sensitive to gefitinib than other cells.
Interestingly, sensitive cells, especially in the adenocarci-
noma cell lines, had more Akt phosphorylation with
EGFR phosphorylation than resistant cells in serum-con-
taining conditions (Chi-square test: p = 0.034: total, p =
0.0114: in adenocarcinoma) (Table 1). In eight squamous
cell carcinoma cell lines, PTEN expression seemed to be
inversely correlated with phosphorylation of Akt (Spear-
man's rank order coefficient: r = -0.76, P = 0.04) (Fig. 3).
However, in the other histological types of cells, PTEN
IC50 values for 23 lung cancer cell lines using the MTT assay Figure 1
IC50 values for 23 lung cancer cell lines using the MTT assay. Cell lines were classified as: sensitive (IC50≤1 µM), intermediate-
sensitive (1 µM < IC50≤10 µM), and resistant (10 µM <IC50) to gefitinib. The bars represent the IC50 and standard deviation 
(SD) obtained in three indpendent MTT assays. Point: mean of three independent experiments, bar: ± SD.
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expression did not correlate with phosphorylation of Akt
(Spearman's rank order coefficient: adenocarcinomas: r =
-0.08, P = 0.17, small-cell carcinomas: r = 0.1, P = 0.84).
Mutation Analyses of the EGFR Gene and K-Ras Gene
Correlations have been reported between EGFR mutation
and clinical responsiveness to gefitinib [7,8]. Therefore,
exons 18, 19, and 21 in the EGFR gene were sequenced
from 23 lung cancer cell lines, in order to assess mutations
in the tyrosine kinase domain. The PC9 cell line, which
was sensitive to gefitinib, had an in-frame deletion within
the EGFR gene, removing amino acids 746 through 750
(delE746-A750) within the activation loop of the tyrosine
kinase that flanks the ATP cleft. The other lung cancer cell
lines did not display any EGFR gene mutations in these
regions. A549(intermediate-sensitive) and LCKJ(resist-
ant) cell lines had a point mutation(G12S) in codon 12
evaluated by K-ras gene mutational analyses.
FISH Analysis
Genomic gains of the EGFR gene were examined by FISH
analysis. PC9 (highly-sensitive cell) with EGFR mutation,
and PC14 (intermediate-sensitive cell) both had EGFR
gene amplification (Fig. 6) [9,19]. There were high levels
of expression and phosphorylation of EGFR in PC9 and
PC14.
Effect of Gefitinib on the Phosphorylation of EGFR, Akt, 
p44/42 MAP kinase, and p38 MAP kinase
The effect of gefitinib was investigated on the phosphor-
ylation of EGFR, Akt, p44/42 MAP kinase, and p38 MAP
kinase, in serum-starved, gefitinib-pretreated lung cancer
Western blot analyses: protein expression and phosphorylation of epidermal growth factor receptor (EGFR), Akt, PTEN,  Her2, Her3, p44/42 mitogen activated protein kinase (MAPK), and p38 MAPK in adenocarcinoma cell lines cultured for 24 h  with (+) or without (-) serum Figure 2
Western blot analyses: protein expression and phosphorylation of epidermal growth factor receptor (EGFR), Akt, PTEN, 
Her2, Her3, p44/42 mitogen activated protein kinase (MAPK), and p38 MAPK in adenocarcinoma cell lines cultured for 24 h 
with (+) or without (-) serum.
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cells (Figs. 7 and 8). Akt and EGFR were phosphorylated
without ligand stimulation in the highly gefitinib-sensi-
tive cell line PC9, which has an EGFR gene mutation, as
well as intermediate-sensitive cell line. Akt and EGFR
phosphorylation were inhibited by gefitinib in sensitive
cell lines (Figs. 7 and 8). With EGF stimulation, phospho-
rylation of Akt increased further in A549 and PC9 cells,
but not in PC14 and ABC-1 cells. In the resistant cell lines,
Akt was phosphorylated through gefitinib treatment,
although EGFR phosphorylation was inhibited (Figs. 7
and 8). In PC9 cells, phosphorylation of p44/42 MAP
kinase was inhibited at low concentrations of gefitinib.
However, in cells showing intermediate sensitivity to
gefitinib, phosphorylation of p44/42 MAP kinase was not
clearly inhibited, either in the presence or absence of EGF.
Phosphorylation of p38 MAP kinase was not clearly
inhibited in anyof the lung cancer cell lines.
Eight of the nine lines showing sensitivity to gefitinib had
Akt phosphorylation without ligand stimulation, while
only three of the 14 resistant lines displayed this charac-
teristic. Furthermore, the ratio of phospho-Akt to total Akt
in sensitive cells was higher than that observed in resistant
cells. Akt phosphorylation was partially inhibited by gefit-
inib in highly and intermediate-sensitive cell lines. These
results suggest that Akt activation without ligand stimula-
tion may play a key signaling role in gefitinib sensitivity.
Summary of expression of PTEN and phosphorylation of Akt in 23 lung cancer cell lines grown under serum-containing (cross  bars) and serum-free (black bars) conditions Figure 3
Summary of expression of PTEN and phosphorylation of Akt in 23 lung cancer cell lines grown under serum-containing (cross 
bars) and serum-free (black bars) conditions. (A) The ratio of phosphorylated Akt signal/total Akt signal (pAkt/Akt); (B) the 
ratio of PTEN signal/β-actin signal; The density of expression of each of the molecules was measured by NIH Image. Point: mean 
of three independent experiment; bars, ± standard deviation (SD). The expression ratio of the molecules in serum-free condi-
tions was compared between gefitinib-resistant and gefitinib-sensitive cell lines using the Mann-Whitney test; point, mean, bars, 
± standard error (SE). *P < 0.05 was considered to be statistically significant.
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Discussion
Clinically, gefitinib-sensitive tumors have been observed
that contain no evidence of activating mutations in the
EGFR gene [20]. We examined the sensitivity of 23 lung
cancer cell lines to gefitinib using the MTT cell prolifera-
tion assay and identified one highly gefitinib-sensitive
lung cancer cell line (PC9), eight intermediate-sensitive
lung cancer cell lines, and 14 resistant lung cancer cell
lines. The IC50 value of the PC9 cell line was about one-
sixth of the clinical dose. Only the PC9 cell line displayed
a mutational event in the EGFR gene: a 15 bp deletion in
exon 19. The IC50 values in the intermediate-sensitive cell
lines ranged between 1 and 10 µM, which was similar to a
previous report [21]. In our study, the IC50 value in A549
cells was 10 µM, which has been previously reported in a
xenograft model as sensitive to gefitinib [22,23]. These
values are higher than the maximum serum concentration
of gefitinib observed in patients (~1 µM). Nevertheless, in
vitro  studies occasionally do not correlate with in vivo
work. However, these differences in this study mainly
seem to depend on the exposure time to gefitinib. In the
xenograft study, A549 was sensitive in gefitinib-intake for
35 days. In our study, Akt phosphorylation was partially
inhibited by gefitinib (<1 µM) in intermediate-sensitive
cell lines, whereas their IC50 value ranged between 1 and
10 µm.
In this study, cancer cell lines showing sensitivity to gefit-
inib exhibited more phosphorylation of Akt and EGFR
without ligand stimulationthan gefitinib-resistant cell
Summary of expression of Her3 and phosphorylation of p44/42 MAPK in 23 lung cancer cell lines grown under serum-contain- ing (cross bars) and serum-free (black bars) conditions Figure 4
Summary of expression of Her3 and phosphorylation of p44/42 MAPK in 23 lung cancer cell lines grown under serum-contain-
ing (cross bars) and serum-free (black bars) conditions. (A) the ratio of phosphorylated p44/42 MAPK signal/total p44/42MAPK 
signal (MAPKp-p44/42/MAPKp44/42); (B) the ratio of Her3 signal/β-actin signal; The density of expression of each of the mole-
cules was measured by NIH Image. Point: mean of three independent experiment; bars, ± standard deviation (SD). The expres-
sion ratio of the molecules in serum-free conditions was compared between gefitinib-resistant and gefitinib-sensitive cell lines 
using the Mann-Whitney test; point, mean, bars, ± standard error (SE). *P < 0.05 was considered to be statistically significant.
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Table 1: Phosphorylation and expression of the molecules and their relationship to gefitinib sensitivity
Expression of the molecules: (+) positive; (-) negative P
Phosphorylated Akt/Akt (+) 0.0059**
PTEN/β-actin (+) 0.361
phospho-p44/42/p44/42 (+) 0.852
phospho-p38/p38 (+) >0.99
phospho-EGFR/EGFR (+) 0.0319**
Her2/β-actin (+) 0.0344**
Her3/β-actin(+) 0.5582
phospho-EGFR(+) phospho-Akt(+) 0.0344**
(vs phospho-EGFR(-) or phospho-Akt(-))
The relationship between gefitinib-sensitivity and the expression of these molecules was investigated by the Chi-square test. **P < 0.05 was 
considered to be statistically significant.
Summary of expression of Her2 and phosphorylation of EGFR in 23 lung cancer cell lines grown under serum-containing (cross  bars) and serum-free (black bars) conditions Figure 5
Summary of expression of Her2 and phosphorylation of EGFR in 23 lung cancer cell lines grown under serum-containing (cross 
bars) and serum-free (black bars) conditions. (A) the ratio of phosphorylated EGFR signal/EGFR signal; (B) the ratio of Her2 
signal/β-actin signal. The density of expression of each of the molecules was measured by NIH Image. Point: mean of three inde-
pendent experiment; bars, ± standard deviation (SD). The expression ratio of the molecules in serum-free conditions was com-
pared between gefitinib-resistant and gefitinib-sensitive cell lines using the Mann-Whitney test; point, mean, bars, ± standard 
error (SE). *P < 0.05 was considered to be statistically significant.
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lines (Mann-Whitney test:P = 0.0016, P = 0.0274, respec-
tively). Sensitive cells frequently had phospho-Akt and
phospho-EGFR without ligand stimulation (P = 0.0059, P
= 0.0319; Chi-square test). This is the first report suggest-
ing that unstimulated phosphorylation of Akt seems to
have a strong correlation with gefitinib sensitivity, espe-
cially, intermediate sensitivity. Unstimulated phosphor-
ylation of Akt seems to be mainly due to constitutive
activation of the Akt signaling pathway. Cappuzzo et al
have reported that patients with phospho-Akt-positive
tumors who received gefitinib had a better response rate
in terms of stable disease, disease control rate, and time to
disease progression than patients with phospho-Akt-neg-
ative tumors [24]. Our results support these clinical find-
ings. In our study, Akt phosphorylation was inhibited by
gefitinib in all these cell lines. In this situation, there
remains a question whether Akt is really so central in
determining the sensitivity to gefitinib or if it is just a
downstream molecule that is sensing activation of other
upstream molecules. Amann et al reported that the
NSCLC cell line H1819, which does not have an EGFR
mutation, but shows high expression levels of EGFR,
ErbB2, and ErbB3, showed intermediate sensitivity to
tyrosine kinase inhibitors [25]. They also reported that, in
this cell line, Akt was constitutively phosphorylated, but
remained prone to inhibition by an EGFR-directed tyro-
sine kinase inhibitor. They suggested that, in addition to
EGFR gene mutation, other factors, such as high expres-
sion levels of ErbB family members, might constitutively
activate Akt and sensitize cells to EGFR inhibitors [25].
The EGFR family (EGFR, Her2 and Her3) operates a com-
plex the signal transduction of its downstream with makes
the formation of each receptor homo- or heterodimerza-
tion and transducecascade through PI3K-Akt and Ras-Erk-
MAPK pathways. Over expression of Her2 has been
shown to promote the constitutive phosphorylation of
EGFR and to delay and prolong the phosphorylation of
EGFR [26]. In our study, there were statistically significant
differences in Her2 expression between gefitinib-sensitive
and resistant cells (P = 0.0344; Chi-square test). Unstimu-
lated phosphorylation of Akt might be a hallmark of sens-
ing activation of other upstream molecules.
In highly- and intermediate-sensitive cells, Akt was phos-
phorylated without ligand stimulation. Clinical markers
of Akt activation without ligand stimulation should be
Fluorescence in situ hybridization (FISH) analyses of lung cancer cell lines, and EGFR mutations and expression Figure 6
Fluorescence in situ hybridization (FISH) analyses of lung cancer cell lines, and EGFR mutations and expression. EGFR gene 
copy numbers were counted and were classified into six FISH strata [9,19]. EGFR gene amplification was detected in PC9 and 
PC14 cells. In the ABC1 cell line, the EGFR gene copy number was five in over 40% of cells (high polysomy:FISH negative); in 
the PC7 and LCKJ cell lines, the EGFR gene copy number was three in over 40% of cells (high trisomy:FISH negative).
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looked for. The eight cell lines with Akt phosphorylation
without ligand stimulation consisted of: five adenocarci-
nomas, one squamous cell carcinoma, and two small-cell
carcinomas. All five adenocarcinomas had EGFR phos-
phorylation (Figs. 2, 3 and 5). In all the adenocarcinoma
lines, the phosphorylation state of EGFR was predictive of
Akt phosphorylation without ligands stimulation (Figs. 2,
3 and 5). Both PC9 (gefitinib-sensitive cell line) with
EGFR mutation, and PC14 (intermediate-sensitive cell
line) had EGFR gene amplification. These lines had the
EGFR and Akt phosphorylation without ligand stimula-
tion. Overall, these results suggested that EGFR and Akt
activations without ligand stimulation might be partially
due to EGFR mutation including amplification. One squa-
mous cell carcinoma had the loss of PTEN protein. Two
small-cell carcinoma cell lines with Akt phosphorylation
without ligand stimulation, H69 and SBC3, exhibited
intermediate sensitivity to gefitinib (Fig. 3). However,
they had little EGFR expression and phosphorylation. It is
possible that gefitinib may block signal transduction via
different receptors including the EGFR family or that
SCLC cells may have small amounts of functional EGFR
that cannot be detected by Western blotting. H69 had a
moderate amount of Her2 expression.
EGF stimulation further increased the phosphorylation of
Akt in A549 and PC9 cells, but not in PC14 and ABC-1
cells. A549 and PC9 had EGF responsiveness as well as
EGFR and Akt phosphorylation without ligand stimula-
tion. In PC9 cells, the phosphorylation of p44/42 MAP
Lung cancer cell lines: Effect of gefitinib on phosphorylated EGFR(p-EGFR), phosphorylated Akt (p-Akt) and the molecules in  the Ras/MEK/Erk pathway with or without EGF Figure 7
Lung cancer cell lines: Effect of gefitinib on phosphorylated EGFR(p-EGFR), phosphorylated Akt (p-Akt) and the molecules in 
the Ras/MEK/Erk pathway with or without EGF.
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kinase was inhibited at low concentrations of gefitinib. In
cell lines with intermediate sensitivity to gefitinib, the
phosphorylation of p44/42 MAP kinase was not clearly
inhibited, either with or without EGF. These phenomena
may be due to differences in activating mechanisms. Lung
cancer cells with phosphorylation of p44/42 MAP kinase
had no K-ras gene mutation other than LCKJ. Han et al
reported that only 18.1% of patients with p-Erk positive
tumors harbored K-ras gene mutation, and identification
of other molecular mechanisms leading to p-Erk activa-
tion and gefitinib resistance was mandatory [18]. There
was no correlation between gefitinib sensitivity, including
intermediate-sensitivity, and the status of the K-ras gene in
our study.
Conclusion
Our report indicates that sensitivity to gefitinib is related
to thephosphorylation of Akt without ligand stimulation.
The phosphorylated state of EGFR and Akt might be clin-
ical markers of Akt activation without ligand stimulation
and increase specificity of gefitinib sensitivity and, there-
fore, may prove to be useful prognostic tests of tumor
responsiveness, in addition to EGFR gene mutation and
amplification. These findings seem to apply especially to
adenocarcinomas. Furthermore, EGFR phosphorylation
may be an attractive candidate for bioimaging for use in
the design of EGFR-targeted therapies.
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